STAAR Surgical (NASDAQ:STAA) Full Year 2024 Results

Key Financial Results

• Revenue: US$313.9m (down 2.6% from FY 2023).
• Net loss: US$20.2m (down by 195% from US$21.3m profit in FY 2023).
• US$0.41 loss per share (down from US$0.44 profit in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

STAAR Surgical Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 8.4%. Earnings per share (EPS) was also behind analyst expectations.

The primary driver behind last 12 months revenue was the China segment contributing a total revenue of US$161.0m (51% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to US$108.3m (42% of total expenses). Explore how STAA's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are down 28% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We have a graphic representation of STAAR Surgical's balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.